“March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”, or “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day compliance period, as specified under Nasdaq L”
“December 30, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closi”
“January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu”
“On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.”
“On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.”
“he statements made by the Company in this Item 4.01 insofar as they relate to Grant Thornton’s audit services and engagement as the Company’s independent registered public accounting firm. Grant Thornton has furnished a letter addressed to the SEC, a copy of which is attached hereto as Exhibit 16.1. (b) Appointment of New Independent Registered Public Accounting Firm On July 1, 2025, the Company engaged Haskell & White LLP (“Haskell & White”) as the Company’s independent registered”
“ismissal of Former Independent Registered Public Accounting Firm On June 30, 2025, Ernexa Therapeutics Inc. (the “Company) dismissed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm effective immediately.”
“On February 10, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (collectively, “Computershare”),”
“In connection with the Offering, the Company also entered into a securities purchase agreement (each, a “Purchase Agreement”) with certain investors who purchased Shares, Pre-Funded Warrants and Warrants in the Offering.”
“On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Brookline Capital Markets, a division of Arcadia Securities, LLC”
“On May 1, 2026, Ernexa Therapeutics Inc. (the “Company”), filed a certificate of amendment (the “ Certificate of Amendment ”) to the Company’s Restated Certificate of Incorporation, as amended with the Secretary of State of Delaware to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-25 (the “ Reverse Stock Split ”).”
“Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.”
Highest-materiality recent filing
Ernexa Therapeutics effects 1-for-25 reverse stock split, effective May 4, 2026
Reverse stock split at 1-for-25 ratio; trading on split-adjusted basis began at market open on May 4, 2026.
Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
Ernexa Therapeutics dismisses Grant Thornton, appoints Haskell & White as auditor
Dismissal of Grant Thornton effective June 30, 2025; appointment of Haskell & White effective July 1, 2025, approved by Audit Committee.
Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.
Ernexa shareholders approve reverse stock split, share increase to 150M, and written consent
Elected all five director nominees: James Bristol, Peter Cicala, Sanjeev Luther, Elena Ratner, William Wexler.
Eterna Therapeutics raises up to $7.3M in private placement; resets annual meeting to June 2
Initial closing on April 2: sold 9.93M shares and 509,736 pre-funded warrants for $1.1M.
Eterna receives Nasdaq delisting notice for low MVLS; board changes
Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.
Notice received December 30, 2024: closing bid price below $1 for 30 consecutive business days.
Stockholders approved issuance of shares for September 2024 transactions at Oct 29 annual meeting.
Eterna raises $3.9M via 12% notes; proposes debt/warrant exchange for 38.3M shares
Closed $3.9M 12.0% senior convertible note private placement; net proceeds for general corporate purposes.
On Sept 17, 2024, Nasdaq determined Eterna did not meet the extension terms to demonstrate compliance with the Minimum Stockholders' Equity Rule (stockholders' equity < $2.5M as of Dec 31, 2023).
On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.
On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.
Max materiality 0.80 · Median 0.60 · Most common event other_material